Liposome adjuvant, temperature-sensitive gel and temperature-sensitive gel preparation

Abstract

The invention specifically discloses a liposome adjuvant, a temperature-sensitive gel and a temperature-sensitive gel preparation. The liposome adjuvant is prepared from the following components in parts by weight: 1 to 4 parts of DOTAP, 280 to 320 parts of soybean lecithin and 40 to 60 parts of cholesterol. The preparation method comprises the following steps: S1, dissolving DOTAP, soybean lecithin and cholesterol in a solvent; rotating and evaporating the solvent to dryness to obtain a film; s2, adding PBS (Phosphate Buffer Solution) into the film obtained in S1, stirring at 45-55 DEG C for 0.5-1.5 hours, and dissolving the film to obtain a liposome stock solution; s3, enabling the liposome stock solution to pass through a polycarbonate film, and extruding for 20-80 times to obtain the liposome adjuvant. The temperature-sensitive gel is prepared from poloxamer gel and a liposome adjuvant; the temperature-sensitive gel can be used for preparing a temperature-sensitive gel adjuvant. The liposome adjuvant has the advantages that the phase change temperature and viscosity of the temperature-sensitive gel can be adjusted, and the administration efficiency of the temperature-sensitive gel preparation can be improved.

Description

technical field [0001] The application relates to the field of biotechnology, more specifically, it relates to a liposome adjuvant, a thermosensitive gel and a thermosensitive gel preparation. Background technique [0002] Currently approved vaccines (such as hand, foot and mouth vaccines) are mostly injections, which mainly induce a strong systemic immune response. However, most pathogens preferentially infect humans through the mucosal surfaces of the gastrointestinal tract, respiratory tract, genitourinary tract, or eyes, and systemic vaccine delivery against infectious diseases routinely used by injection fails to induce strong mucosal immune responses. [0003] The nasal cavity has a high density of dendritic cells, which can mediate strong systemic and mucosal immune responses against antigens and pathogens that invade the body through the upper respiratory tract, and vaccines can be administered nasally to avoid gastrointestinal disruption; where nasal mucosal deliver...

AI Technical Summary

Problems solved by technology

[0004] However, the absorption of drugs by the nasal mucosa is limited. How to improve the bioavailability of nasal mucosal administration is a problem that must be faced when studying nasal mucosal vaccines.